Incremental risk of the Cox-maze IV procedure for patients with atrial fibrillation undergoing mitral valve surgery  by Saint, Lindsey L. et al.
A
C
D
Acquired Cardiovascular Disease Saint et alIncremental risk of the Cox-maze IV procedure for patients with
atrial fibrillation undergoing mitral valve surgeryLindsey L. Saint, MD,a Ralph J. Damiano, Jr, MD,a Phillip S. Cuculich, MD,b Tracey J. Guthrie, RN,a
Marc R. Moon, MD,a Nabil A. Munfakh, MD,a and Hersh S. Maniar, MDaFrom th
Unive
This stu
21 an
Disclosu
receiv
Dr Cu
resear
Socie
Read at
Maui
Receive
public
Address
Wash
Quee
mania
0022-52
Copyrig
http://dx
1072Objective:More than 50% of atrial fibrillation surgery occurs in the setting of mitral valve surgery. Despite this,
no risk models have been validated for concomitant arrhythmia surgery. The purpose of the present study was to
quantify the additional risk of performing the Cox-maze IV procedure for patients undergoing mitral valve
surgery.
Methods: From January 2002 to June 2011, 213 patients with mitral valve disease and preoperative atrial
fibrillation underwent mitral valve surgery only (n ¼ 109) or in conjunction with a Cox-maze IV procedure
(n ¼ 104). The operative mortality for the mitral valve procedure alone was predicted for each group using
the Society of Thoracic Surgeons perioperative risk calculator. The risk attributed to the added Cox-maze IV
procedure was calculated by comparing the predicted mortality rate of an isolated mitral valve procedure and
the actual mortality rate of mitral valve surgery with a concomitant Cox-maze IV procedure.
Results: For patients not undergoing a Cox-maze IV procedure, the predicted and actual postoperative mortality
rate was 5.5% and 4.6% (5 of 109), respectively. For patients receiving mitral valve surgery and a concomitant
Cox-maze IV, the predicted and actual postoperativemortality of the mitral valve procedure was 2.5% and 2.9%
(3 of 104), respectively, and not significantly different. Patients not offered a Cox-maze IV procedure had
significantly more serious comorbidities.
Conclusions: For patients with atrial fibrillation and mitral valve disease undergoing mitral valve surgery, the
decision to offer a concomitant Cox-maze IV procedure will be influenced by the underlying comorbid
conditions. Nonetheless, in selected lower risk patients, the addition of a Cox-maze IV procedure did not
significantly affect the procedural mortality. (J Thorac Cardiovasc Surg 2013;146:1072-7)The Cox-maze procedure was originally designed as a
concomitant procedure by Dr James Cox for the treatment
of atrial fibrillation (AF) in patients undergoing mitral valve
(MV) surgery. However, both the complexity of the
operation and the time required to complete the procedure
limited its clinical application to patients with lone AF for
many years. After several iterations, the Cox-maze IV
(CMIV) procedure was introduced in 2002. The CMIV
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The Journal of Thoracic and Cardiovascular Surincisions of the Cox-maze lesion set with linear lines of
ablation, making the operation technically easier and faster
to perform.1 With the introduction of ablation devices, the
number of surgeries performed in the United States for
the correction of AF more than doubled.2 Currently, more
than 80% of these procedures are completed with the
assistance of ablation technology, and more than 95% are
performed as concomitant operations to other cardiac
surgical procedures.2
For patients undergoing cardiac surgery, the prevalence
of AF is greatest among patients with MV disease.
Concordantly, more than one half of all AF corrective
surgeries performed each year occur in patients undergoing
MV operations.2 Despite the proven efficacy of AF
corrective surgery for patients with AF undergoing MV
surgery, a subgroup of patients with AF and concomitant
MV disease exists that is less likely to be offered surgical
AF correction.3-5 Many possible reasons exist for this
omission, but 1 possibility is that the operating surgeon
believes that an additional operative risk is conferred by
the AF correction procedure itself. Currently, no risk
models are available for concomitant arrhythmia surgery;
thus, the extent of the additional associated risk has been
poorly defined.
Given these data, the importance of characterizing the
additional risk of concomitant AF surgery in this group ofgery c November 2013
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CMIV ¼ Cox-maze IV
MV ¼ mitral valve
STS ¼ Society of Thoracic Surgeons
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quantify the additional risk of performing the CMIV
procedure in selected patients undergoing MV surgery.
METHODS
Participants and Procedure
The CMIV procedure has been previously described and the technique
was similar for all patients during the study period, with the exception of a
‘‘superior connecting lesion’’ that was added in 2005.6 This additional
lesion connected the right and left superior pulmonary veins, isolating
the entire posterior left atrium as part of the ‘‘box-lesion set.’’6 Of the
patients who underwent MV surgery with a concomitant CMIV, 89%
(n ¼ 92) had a ‘‘box lesion set.’’ Pulmonary vein isolation was confirmed
when possible in all patients undergoing a CMIV procedure by demonstra-
tion of an exit block from each of the pulmonary veins. Confirmation of an
exit block from the pulmonary veins was not performed in those patients
with a left atrial appendage thrombus precluding cardioversion or in
patients who were unable to be successfully cardioverted at surgery.
To determine the additional risk conferred by the CMIV procedure for
patients undergoing MV surgery, the operative mortality for the MV
procedure alonewas predicted for each group using the Society of Thoracic
Surgeons (STS) perioperative risk calculator. The risk attributed to the
added CMIV procedure was calculated by comparing the predicted
mortality rate of an isolated MV procedure and the actual mortality rate
of MV surgery with a concomitant CMIV procedure. Late death was
defined as all-cause mortality occurring at a median follow-up of 2.3 and
3.3 years (interquartile range, 1.2-5.2 and 1.8-6.2) for the patients
undergoing isolated MV surgery and MV surgery with concomitant
CMIV, respectively, as determined by individual patient follow-up
according to the Social Security Death Index.
The Washington University School of Medicine institutional review
board approved the present study. Each participant provided informed
-consent and permission for release of information.
Statistical Analysis
Continuous variables are expressed as the mean standard deviation or
as the median and interquartile range (25%-75%) if the data were not
normally distributed. Categorical variables are expressed as frequencies
and percentages. Categorical outcomes were compared using either the
chi-square or Fisher exact test. Continuous outcomes were compared using
the t test for mean values of normally distributed continuous variables and
the Wilcoxon rank sum nonparametric test for skewed distributions.
Significant covariates identified by univariate analysis (P  .10) or
covariates deemed clinically relevant were entered into a multivariate
binary logistic regression analysis. Twelve preoperative and perioperative
variables were evaluated using multivariate analysis to identify the
predictors of 30-day mortality and late death. These included age, preoper-
ative renal failure, diabetes mellitus, chronic obstructive pulmonary
disease, previous myocardial infarction, hypertension, hyperlipidemia,
cerebrovascular disease, previous cerebrovascular accident, previous
coronary artery bypass grafting, previous valve surgery, and concomitant
CMIV procedure. All data analyses were done using the Statistical Package
for Social Sciences, version 20.0, for Windows (SPSS Inc, Chicago, Ill).The Journal of Thoracic and CarRESULTS
From January 2002 through June 2011, 213 patients with
preoperative AF and concomitant MV disease underwent
MV surgery only (n ¼ 109) or combined with a CMIV
procedure (n ¼ 104).
Although the patients in the 2 groups were similar with
regard to age, gender, New York Heart Association
classification, and preoperative ejection fraction, the groups
differed with respect to several comorbidities (Table 1).
Patients in whom a concomitant CMIV was not performed
were more likely to have renal failure (P< .01), diabetes
mellitus (P ¼ .02), chronic obstructive pulmonary disease
(P< .01), hyperlipidemia (P ¼ .01), previous myocardial
infarction (P < .01), previous cerebrovascular accident
(P<.01), and previous coronary artery bypass grafting or
valve surgery (P< .01). The increased comorbidities in
this group were reflected in a predicted STS 30-day
mortality score of 5.5%, which was significantly greater
than the predicted mortality score of 2.5% for the patients
who underwent MV surgery and concomitant CMIV
(P<.01).
The types of MV pathologic features also differed signi-
ficantly between the 2 groups (Table 2). The distribution of
the etiology of MV disease was skewed for patients
undergoing MV surgery with concomitant CMIV, favoring
etiologies such as rheumatic heart disease, mitral stenosis,
annular dilatation, and degenerative disease. In contrast,
the distribution of the etiology of MV disease for patients
in the isolated MV surgery group was skewed to reflect a
history of endocarditis and ischemic disease (P < .01).
Despite the difference in etiology of MV disease, the
2 groups were similar with regard to the coexistence of
pulmonary hypertension and their MV dysfunction
(69% vs 63%, P ¼ .39).
Of the patients who underwent MV surgery with
concomitant CMIV, 41% had paroxysmal AF, 16% had
persistent AF, and 43% had long-standing persistent AF.
Eleven percent of patients in this group had a previous failed
catheter ablation. The mean duration of AF in this group
was 60.2  89.4 months. However, the AF history of
patients not offered CMIV was not well characterized
with respect to the AF type and duration.
The MV procedures performed were similar between the
groups (P ¼ .17), as was the use of bioprosthetic valves in
the case of MV replacement surgery (P¼ .55, Table 3). The
aortic crossclamp and cardiopulmonary bypass times
were significantly longer in patients undergoing MV
surgery with a concomitant CMIV procedure (93  23
and 187  40 minutes) than in patients who underwent
isolated MV surgery (80  35 and 126  60 minutes,
respectively, P<.01). Importantly, the amount of additional
crossclamp time required to perform the CMIV was
minimal, averaging only 13 minutes between the 2 groups.diovascular Surgery c Volume 146, Number 5 1073
TABLE 3. Perioperative details
Variable
Lone MV
(n ¼ 109)
MV plus CMIV
(n ¼ 104)
P
value
Urgent or emergent procedure 3 (3) 1 (1) .62
Required IABP intra- or
postoperatively
15 (14) 4 (4) .02
MV replacement 60 (55) 47 (45) .17
Bioprosthetic replacement
valve
40 (67) 28 (60) .55
Aortic crossclamp time (min) 80  35 93  23 <.01
CPB time (min) 126  60 187  40 <.01
LAA thrombus 0 (0) 4 (4) .06
Lesion set NA
Box 82 (89)
Nonbox 12 (12)
Data presented as n (%) or mean  standard deviation. IABP, Intra-aortic balloon
pump; CPB, cardiopulmonary bypass; LAA, left atrial appendage; MV, mitral valve;
CMIV, Cox-maze IV; NA, not applicable.
TABLE 1. Demographics
Variable
Lone MV
(n ¼ 109)
MV plus CMIV
(n ¼ 104)
P
value
Age (y) 65.6  13.2 63.5  11.8 .21
Women 53 (49) 57 (55) .41
NYHA class III or IV 84 (77.1) 74 (71) .35
Ejection fraction (%) 50  14 51  11 .17
Renal failure 12 (11) 1 (1%) <.01
Diabetes 29 (27) 14 (14) .02
COPD 41 (38) 20 (19) <.01
Hyperlipidemia 63 (58) 42 (40) .01
Previous MI 30 (28) 4 (4) <.01
Previous CVA 20 (18) 5 (5) <.01
Previous CABG 22 (20) 3 (3) <.01
Previous valve operation 44 (40) 12 (12) <.01
Predicted STS operative
mortality (%)
5.5  5.2 2.5  1.9 <.01
Data presented as mean  standard deviation or n (%). MV, Mitral valve;
CMIV, Cox-maze IV; NYHA, New York Heart Association; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction; CVA, cerebrovascular
accident; CABG, coronary artery bypass grafting; STS, Society of Thoracic Surgeons.
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DIsolated MV patients were more likely to require an
intraoperative or postoperative balloon pump (P ¼ .02),
and other perioperative features, such as surgical status
and the presence of thrombus in the left atrial appendage
were no different between the 2 groups.
Postoperatively, the MV surgery and concomitant CMIV
group required fewer blood products (P<.01). However, no
differences were found in the postoperative outcomes with
regard to the rates of stroke, reoperation for bleeding,
postoperative renal failure, and length of stay in the
intensive care unit (Table 4). The patients who underwent
MV surgery with a concomitant CMIV procedure
experienced a greater incidence of early atrial tachyar-
rhythmia (P<.01) than did patients who underwent isolated
MV surgery.
The observed 30-day mortality for patients not offered a
CMIV procedure at their MV surgery was 4.6% (expected
5.5%), yielding an observed/expected 30-day mortalityTABLE 2. Valve pathologic features
Variable
Lone MV
(n ¼ 109)
MV plus CMIV
(n ¼ 104)
P
value
MV disease etiology <.01
Calcific 2 (2) 5 (5)
Endocarditis 15 (14) 1 (1)
Myxomatous 32 (30) 42 (41)
Rheumatic 20 (18) 34 (33)
Prosthetic valve failure 18 (17) 5 (5)
Annular dilatation 7 (6) 17 (16)
Ischemic 15 (14) 0
Mitral stenosis 24 (22) 37 (36) .03
Pulmonary hypertension 75 (69) 65 (63) .39
Data presented as n (%). MV, Mitral valve; CMIV, Cox-maze IV.
1074 The Journal of Thoracic and Cardiovascular Surratio of 0.84 (95% confidence interval, 0.13-1.54) in
this group. The observed 30-day mortality for patients
undergoing MV surgery with a concomitant CMIV
procedure was 2.9%. The STS predicted score for isolated
MV surgery in this group was 2.5%. The resultant
observed/expected 30-day mortality ratio was 1.16 (95%
confidence interval, 0.13-2.44), and the difference was not
statistically significant.
On multivariate analysis, the only significant predictor of
30-day mortality for either group was age. However, at a
median follow-up of 2.3 and 3.3 years (interquartile range,
1.2-5.2 and 1.8-6.2 years for patients undergoing isolated
MV surgery and MV surgery with a concomitant CMIV,
respectively), age, chronic obstructive pulmonary disease,
cerebrovascular disease, previous myocardial infarction,
and renal failure were significant predictors of late death.
The addition of a concomitant CMIV procedure was
identified as protective from late death, and this trend nearly
reached statistical significance (P ¼ .06).
In patients with AF who underwent a concomitant CMIV
procedure at MV surgery, freedom from AF and atrial
tachyarrhythmia was 85%, 91%, and 84% at 3, 6, and
12 months, respectively. Freedom from AF and atrial
tachyarrhythmia without antiarrhythmic medications in
this population was 54%, 77%, and 77% at 3, 6, and
12 months, respectively.
DISCUSSION
A substantial increase in arrhythmia surgery has occurred
in recent years owing to both the increase in AF frequency
in our aging population and the introduction of ablative
technologies that have made AF correction procedures
easier to perform. Because AF correction procedures are
most commonly performed as concomitant operations
with other cardiac procedures, the ability to determine the
incremental risk incurred by a concomitant AF correctiongery c November 2013
TABLE 4. Postoperative morbidity
Variable Lone MV (n ¼ 109) MV plus CMIV (n ¼ 104) P value
Operative mortality 5 (5) 3 (3) .72
Stroke 2 (2) 1 (1) .99
Pneumonia 19 (17) 10 (10) .11
Ventilation time (h) 20 (IQR, 11-49) 17 (IQR, 6-42) .09
Required reintubation 9 (8) 6 (6) .60
Reoperation for bleeding 9 (8) 4 (4) .25
Postoperative infusion of blood products 85 (78) 58 (56) <.01
Deep sternal wound infection 1 (1) 0 (0) .99
Renal failure 8 (7) 8 (8) .99
Heart block 2 (2) 6 (6) .16
Early atrial tachyarrhythmias 10 (9) 62 (60) <.01
Postoperative pacemaker placement 5/80 (6) 11/96 (11) .30
Length of stay in ICU (h) 79 (IQR, 45-143) 73 (IQR, 44-129) .40
Data presented as n (%) or median (IQR). ICU, Intensive care unit; IQR, interquartile range; MV, mitral valve; CMIV, Cox-maze IV.
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decision-making and counseling of the surgical patient.
In our series, patients who were not offered a con-
comitant CMIV with their MV surgery were generally
more ill, with more comorbidities than those in whom a
CMIV was performed. A paucity of data was available
characterizing the AF type these patients experienced
preoperatively, a recognized weakness of the present study.
Not surprisingly, both the observed and expected risks of
30-day mortality were greater for these higher risk patients
than the observed and expected mortality rates for the lower
risk patients who had undergone a concomitant CMIV
procedure.
The STS perioperative risk calculator, the use of which is
becoming more commonplace in clinical trials and
other arenas, was accurate in predicting the risk for this
population of patients.7 This risk calculator has previously
been validated in patients undergoing isolated mitral valve
procedures and in patients undergoing other cardiac
surgical procedures, most notably aortic valve surgery.8,9
Despite the multiple comorbidities present in these
patients, the only predictor in the higher risk isolated MV
surgery group for 30-day mortality on multivariate
analysis was age, consistent with reported series of MV
procedures.10
The principle finding of our investigation was that, for
properly selected patients at an experienced center, the
addition of a CMIV procedure to MV surgery did not add
any incremental risk to the patients. In the present study,
the observed 30-day mortality for patients undergoing a
concomitant CMIV procedure was not different from that
predicted for isolated MV surgery for these patients.
Although the CMIV procedure did require an increase in
cardiopulmonary bypass time and a small increase in
ischemic time, no additional quantifiable risk with respect
to death, stroke, or major postoperative morbidity could
be identified. The only increased postoperative morbidityThe Journal of Thoracic and Carassociated with this group was the presence of early atrial
tachyarrhythmia, which is common in patients undergoing
a CMIV procedure and has been shown to have no
demonstrable effect on the late recurrence of AF.11
The findings of the present investigation were consistent
with other published reports regarding the additional risk
of concomitant arrhythmia surgery performed at MV
surgery.2,3,12 However, unlike previous reports, the present
study was the first to examine the effect of a single
arrhythmia procedure, the CMIV procedure, on the
perioperative morbidity and mortality when performed
with MV surgery. Other reports have been hampered
because ‘‘arrhythmia surgery’’ is often an amalgamation
of a wide variety of procedures ranging from pulmonary
vein isolation to a traditional cut and sew Cox-maze III,
each with a very distinct risk and benefit profile. Addition-
ally, our series is unique in that the cohorts were
homogeneous with respect to valvular heart disease and
described only patients undergoing isolated mitral valve
surgery. The only surgical variable in the present study
was the presence or absence of a concomitant CMIV
procedure.
A recognized weakness of the present study was that the
group of patients with AF who received concomitant CMIV
was a selected lower risk population. The lesser extent to
which the these patients experienced preoperative comorbid
conditions was reflected in the treatment assignment bias
evident in the present study, such that the operating surgeon
made a decision that these patients should be able to tolerate
the additional surgical time and manipulation incurred by a
concomitant CMIV procedure. The judgment and skill of an
experienced MV and arrhythmia surgeon cannot be under-
estimated and is perhaps the most responsible for the low
morbidity and mortality demonstrated in the present series.
It is likely that the incorporation of ablation technology is
also largely responsible for the lack of increased risk
demonstrated in the present series of concomitant CMIVdiovascular Surgery c Volume 146, Number 5 1075
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Dpatients. Ablation technology simplifies the technical
aspects of performing the Cox-maze lesion set and reduces
the procedural crossclamp and cardiopulmonary bypass
times compared with the traditional Cox-maze III
procedure.13 Fewer incisions are required, minimizing
bleeding complications, and newer technologies have
allowed for minimal collateral tissue damage, if correctly
applied.14-17 Finally, MV surgery is particularly well
suited to the addition of a CMIV procedure, compared
with coronary artery bypass grafting or aortic valve
procedures. Performing a concomitant CMIV procedure
with of MV surgery is relatively straightforward and does
not require changes in surgical strategy, because the atrial
incisions and cannulation sites for cardiopulmonary
bypass are not necessarily different from those required
for an isolated MV procedure.
The number of patients with AF and concomitant MV
disease has continued to increase as the population ages
and represents a group of patients that could derive substan-
tial benefit from surgical AF correction. The benefits of AF
corrective surgery include fewer bleeding complications
from chronic anticoagulation and a decreased risk of throm-
boembolism and subsequent stroke.18 Moreover, it has been
shown in several studies that patients with AF and con-
comitant MV disease are unlikely to experience a return
to normal sinus rhythm after MV surgery alone.3,5 In
contrast, the efficacy of the CMIV procedure in these
patients has been excellent, with a rate of freedom from
AF and atrial tachyarrhythmia of 85%, 91%, and 84% at
3, 6, and 12 months in the present series, respectively.
The rate of freedom from AF and atrial tachyarrhythmia
without antiarrhythmic medications in this population was
54%, 77%, and 77% at 3, 6, and 12 months, respectively.
Although not demonstrated in the present series, the
CMIV procedure does have its own attendant risks,
including the greater rate of permanent pacemaker
implantation in patients undergoing concomitant CMIV at
MV surgery.2 However, the benefits of restoration of sinus
rhythm, and the consequential diminutive risk of
chronic anticoagulation or stroke likely outweigh these
risks.12,18-20 Additionally, although it did not reach
significance in the present study, the addition of a CMIV
procedure to MV surgery in select patients was associated
with a protective effect against late death.
In conclusion, for select low-risk patients, the addition of
a concomitant CMIV procedure does not appear to increase
the operative risk greater than that expected for MV surgery
alone and produces a high degree of freedom from AF and
antiarrhythmic medications in these patients. Although the
decision to offer a concomitant CMIV procedure at MV
surgery appears to be primarily influenced by underlying
comorbid conditions, the remaining question is whether a
concomitant CMIV procedure should be offered to a wider
population of higher risk patients with AF and MV disease.1076 The Journal of Thoracic and Cardiovascular SurIn the present series, the only predictor of 30-day mortality
in the isolated MV group was age, which might represent
the highest risk group. These data suggest that an advantage
could exist with the addition of a concomitant CMIV
procedure in younger patients, despite the presence of other
comorbidities.
The present study had several recognized limitations. As
reported, the type and duration of AF in our patients who
were not offered a concomitant CMIV procedure with their
MV surgery were not well characterized; thus, it is
unknown whether the preoperative AF burden was
comparable between the 2 groups. Additionally, this was
a single-center retrospective review incorporating cases
performed by 2 principle surgeons, both with substantial
experience in MV and arrhythmia surgery. Furthermore,
the focus of our investigation was the 30-day morbidity
and mortality. Longer follow-up of a larger group of
patients with AF and MV disease is needed to fully
characterize the additional risks and benefits of performing
the CMIV procedure in this group of patients in conjunction
with MV surgery.References
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